Comparative Study
doi: 10.1016/s0145-2126(98)00060-5.
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin
Affiliations
- PMID: 9680113
- DOI: 10.1016/s0145-2126(98)00060-5
Item in Clipboard
Comparative Study
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin
Leuk Res.
1998 Jul.
Abstract
We investigated the cytotoxicity and cellular pharmacology of idarubicin (IDA), idarubicinol (IDAol) and daunorubicin (DNR) in K562/VP-H2 cells, which show topoisomerase II-related multidrug resistance but do not overexpress P-glycoprotein. K562/VP-H2 cells were less resistant to IDA and IDAol than to DNR. There was no significant difference in the accumulation of each drug between K562 and K562/VP-H2 cells. The cleavage of DNA induced by each drug was decreased in K562/VP-H2 cells, however, the decrease in cleavage in K562/VP-H2 cells was less with IDA and IDAol than with DNR. These results suggest that IDA and IDAol have more cytotoxic potency than DNR in topoisomerase II-related multidrug-resistant leukemia cells.
Similar articles
-
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.Biochem Pharmacol. 1995 Nov 9;50(10):1673-83. doi: 10.1016/0006-2952(95)02069-1. Biochem Pharmacol. 1995. PMID: 7503771
-
Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.Leuk Res. 1999 Jan;23(1):37-42. doi: 10.1016/s0145-2126(98)00138-6. Leuk Res. 1999. PMID: 9933133
-
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.Leuk Res. 1999 Jun;23(6):539-48. doi: 10.1016/s0145-2126(99)00041-7. Leuk Res. 1999. PMID: 10374847
-
Selected pharmacologic characteristics of idarubicin and idarubicinol.Leukemia. 1992;6 Suppl 1:70-5. Leukemia. 1992. PMID: 1548940 Review.
-
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.Semin Cancer Biol. 1991 Aug;2(4):235-44. Semin Cancer Biol. 1991. PMID: 1655118 Review.
Cited by
-
A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.Int J Hematol. 2001 Oct;74(3):297-302. doi: 10.1007/BF02982064. Int J Hematol. 2001. PMID: 11721966 Clinical Trial.
-
Mechanisms of drug resistance in acute myeloid leukemia.Onco Targets Ther. 2019 Mar 11;12:1937-1945. doi: 10.2147/OTT.S191621. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881045 Free PMC article. Review.
-
Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors.Cell Death Dis. 2013 Dec 5;4(12):e948. doi: 10.1038/cddis.2013.467. Cell Death Dis. 2013. PMID: 24309935 Free PMC article.
-
Pharmacokinetics and toxicity of idarubicin in the rat.Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):215-9. doi: 10.1007/BF03226374. Eur J Drug Metab Pharmacokinet. 2001. PMID: 11808862
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
